Moleculin Biotech (NASDAQ:MBRX) Rating Lowered to Strong Sell at Wall Street Zen

Moleculin Biotech (NASDAQ:MBRX) was downgraded by investment analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Several other brokerages have also commented on MBRX. HC Wainwright dropped their price objective on Moleculin Biotech to $60.00 and set a “buy” rating on the stock in a report on Friday, August 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Moleculin Biotech in a research note on Thursday, October 15th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Moleculin Biotech presently has a consensus rating of “Hold” and a consensus target price of $60.00.

Moleculin Biotech Price Performance

MBRX opened at $8.70 on Friday. The firm has a fifty day moving average price of $10.45 and a 200 day moving average price of $38.83. Moleculin Biotech has a 1 year low of $3.23 and a 1 year high of $253.05. The stock has a market cap of $8.93 million, a P/E ratio of -0.06 and a beta of 2.11.

Moleculin Biotech (NASDAQ:MBRX) last released its quarterly earnings results on Thursday, August 13th. The company reported ($28.00) EPS for the quarter, beating the consensus estimate of ($31.00) by $3.00. Equities analysts expect that Moleculin Biotech will post -47.40 EPS for the current year.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on developing treatments for cancers and other serious diseases. The company uses its proprietary technology platforms to design drug candidates intended to address treatment resistance, improve drug delivery, and target biological pathways involved in disease progression.

Moleculin’s lead program is Annamycin, a liposomal formulation of the anthracycline doxorubicin being investigated for acute myeloid leukemia and soft-tissue sarcoma.